← boothcheck

BLLN vs GH stock comparison

BillionToOne, Inc. vs GUARDANT HEALTH, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.

The balance sheets tell the strategy: BillionToOne holds a 10.9 current ratio with minimal debt and has already reached a positive 16.5% operating margin, discipline funded by patience; Guardant Health holds a 4.7 current ratio and spends it, a negative 40.2% operating margin in pursuit of cancer-screening scale. The market pays $20B for Guardant's ambition and $6B for BillionToOne's arithmetic. Guardant's negative 22.6% return on assets is the price of building a screening franchise before it pays; BillionToOne's near-1% return is the sound of a young company just crossing into the black. Two liquid-biopsy-era diagnostics stories, one priced on what it spends, the other on what it keeps.

Comparison updated 2026-07-10.

BLLN vs GH: the numbers

MetricBLLNGH
Price$117.95$149.32
Market cap$6.3B$19.6B
SectorMedical DiagnosticsMedical Diagnostics
StageGrowthGrowth
P/B12.37
P/S21.6218.15
EV/EBITDA361.8
Revenue growth+100.6%+39.3%
Gross margin73.0%
Operating margin16.4%-40.2%
Net margin1.7%-40.1%
Return on equity0.9%
Return on assets0.7%-22.6%
Return on invested capital2.0%-26.7%
FCF yield0.4%-1.2%
Debt / equity0.18
Current ratio10.924.68
Altman Z (solvency)6.954.37
Piotroski F (quality)5 / 93 / 9
Full BLLN report → Full GH report →
Get boothcheck's read on BLLN and GH, and what their prices are betting on, in your inbox. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

Compare any two stocks

vs

The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.